Last reviewed · How we verify
Carbidopa Levodopa
At a glance
| Generic name | Carbidopa Levodopa |
|---|---|
| Also known as | Sinemet, Sinemet, L-DOPA |
| Sponsor | University of Washington |
| Drug class | Aromatic Amino Acid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Dyskinesia
- Nausea
- Hallucinations
- Confusion
- Dizziness
- Depression
- Urinary tract infection
- Headache
- Dream abnormalities
- Dystonia
- Vomiting
- Upper respiratory infection
Serious adverse events
- Myocardial infarction
- Psychotic episodes including delusions and paranoid ideation
- Seizures including convulsions
- Syncope
- Angioedema
- Gastrointestinal bleeding
- Agranulocytosis
- Hemolytic anemia
- Henoch-Schönlein purpura
- Depression with suicidal tendencies
Key clinical trials
- Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (NA)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Montelukast in Parkinson Disease (PHASE2, PHASE3)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Levodopa for Diabetic Retinopathy (PHASE2)
- A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (PHASE1)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |